Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
Sara Bonstein filed a notice of proposed sale of common stock of the issuer under Rule 144. The planned sale covers 1,447 common shares through Merrill Lynch on 01/08/2026 on NASDAQ, with an aggregate market value of 252,023 and 213,273,469 shares outstanding.
The 1,447 shares were acquired on 01/06/2026 via stock plan activity from the issuer, with payment also dated 01/06/2026. Over the past three months, the seller reported additional sales of common stock, including 1,678 shares on 01/07/2026 for gross proceeds of 293,766 and 1,517 shares on 01/06/2026 for gross proceeds of 262,941.
Insmed submitted a notice of proposed sale under Rule 144 for 5,138 common shares, to be sold through Merrill Lynch on the NASDAQ around 01/08/2026. The filing lists an aggregate market value of 894,885 for these shares and notes that common shares outstanding total 213,273,469.
The securities to be sold were acquired from the issuer through stock plan activity on 01/04/2026, 01/05/2026, and 01/06/2026 in amounts of 1,603, 1,648, and 1,887 common shares, respectively. The person for whose account the shares are to be sold, identified as Martina Flammer, previously sold common shares over the past three months, including 31,226 shares on 11/11/2025 for gross proceeds of 5,921,820 and 12,303 shares on 01/05/2026 for gross proceeds of 2,108,459.
A shareholder associated with symbol INSM has filed a Form 144 indicating an intention to sell 1,660 shares of common stock through Merrill Lynch on or about 01/08/2026 on the NASDAQ market. The filing notes that 213,273,469 shares of this class of stock were outstanding at the time.
The 1,660 shares to be sold were acquired on 01/06/2026 through stock plan activity from the issuer. The filer, Martina Flammer, also reported several recent sales in the past three months, including 31,226 shares sold on 11/11/2025 for gross proceeds of 5,921,820 and other transactions such as 12,303 shares on 01/05/2026 for gross proceeds of 2,108,459. The signer represents that they are not aware of undisclosed material adverse information about the issuer.
Insmed Inc. insider Roger Adsett filed a notice of proposed sale of 2,059 shares of common stock, with an aggregate market value of 358,616, to be sold on or about 01/08/2026 through Merrill Lynch on the NASDAQ. These shares were acquired on 01/06/2026 via stock plan activity from the issuer. Over the past three months, Adsett has sold 802 common shares for gross proceeds of 140,406 on 01/07/2026 and 1,429 common shares for gross proceeds of 247,688 on 01/06/2026. Shares of the issuer outstanding are reported as 213,273,469.
Insmed Inc. Chief Operating Officer Roger Adsett reported three sales of Insmed common stock in early January. On January 6, 2026, he sold 1,429 shares at $173.33 per share. On January 7, 2026, he sold 802 shares at $175.07 per share, and on January 8, 2026, he sold 2,059 shares at $174.17 per share.
After these transactions, Adsett directly held 107,601 Insmed shares. A footnote explains that the shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units and to cover related broker fees, indicating these were primarily tax-related transactions rather than discretionary sales.
Insmed Inc. reported that its Chief Financial Officer, Sara Bonstein, sold small blocks of common stock on three consecutive days to cover tax obligations tied to equity awards. On January 6, 2026, she sold 1,517 shares at $173.33 per share, on January 7, 2026 she sold 1,678 shares at $175.07 per share, and on January 8, 2026 she sold 1,447 shares at $174.17 per share. According to the filing, these sales were made to satisfy tax withholding obligations upon the vesting of restricted stock units and to cover related broker fees, and she directly owned 80,506 shares of common stock after the final transaction.
Insmed Inc.'s Chief Medical Officer, Martina Flammer, M.D., reported a series of equity transactions in company stock. On January 6, 2026, she exercised a stock option for 8,570 shares of common stock at an exercise price of $26.43 per share, converting a derivative position into directly held stock. That same day, she reported open-market sales of common stock, including 4,783 shares at a weighted average price of $173.47, 2,830 shares at $174.21, and 957 shares at $175.01.
Additional sales included 1,615 shares at $173.33 on January 6, 1,434 shares at a weighted average of $175.84 on January 7, and on January 8, 1,660 shares at a weighted average of $173.87 and 3,251 shares at $174.17. A portion of the shares sold was specifically to satisfy tax withholding obligations upon vesting of restricted stock units and related broker fees. After these transactions, she directly held 86,794 shares of Insmed common stock. All trades noted as (1) were effected under a Rule 10b5-1 trading plan adopted on February 27, 2025.
Insmed Chair and CEO William Lewis reported three sales of Insmed common stock on January 6–8, 2026. He sold 4,096 shares on January 6 at $173.33, 2,357 shares on January 7 at $175.07, and 3,223 shares on January 8 at $174.17, all reported as open market sales.
According to the filing, these shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. After these transactions, Lewis directly held 315,407 shares of Insmed common stock. He also had indirect beneficial ownership of 233,924 shares held by the Katie Procter Dynasty Trust and 50,500 shares held by the William Lewis Family Legacy Trust.
Insmed's chief legal officer reports small share sales tied to tax withholding. Michael Alexander Smith, Chief Legal Officer of Insmed Inc., reported three sales of common stock on January 6–8, 2026. He sold 1,396 shares at $173.33, 709 shares at $175.07, and 1,053 shares at $174.17. After these transactions, he directly beneficially owned 57,037 shares of Insmed common stock. A footnote explains that the shares were sold to satisfy tax withholding obligations upon the vesting of restricted stock units and to cover related broker fees, indicating the sales were driven by tax requirements rather than discretionary trading.
INSM received a Rule 144 notice covering a planned sale of 1,053 shares of its common stock through Merrill Lynch on 01/08/2026, with an aggregate market value of 183401 and listing on NASDAQ. These shares were acquired on 01/06/2026 through stock plan activity from the issuer. The notice reports that 213,273,469 shares of common stock were outstanding. Over the prior three months, Michael Smith reported separate sales of 709, 1,396, and 27,130 common shares with gross proceeds of 124124, 241968, and 4985054, respectively.